about
A framework for cost-effectiveness analysis from clinical trial data.Incorporation of genuine prior information in cost-effectiveness analysis of clinical trial data.The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximation.On estimators of medical costs with censored data.Using rank data to estimate health state utility models.Modelling SF-6D health state preference data using a nonparametric Bayesian method.Modelling covariates for the SF-6D standard gamble health state preference data using a nonparametric Bayesian method.The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the futureInference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare.Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies.Letter to the Editor: Probabilistic population forecasts for informed decision making.A comparison of United States and United Kingdom EQ-5D health states valuations using a nonparametric Bayesian method.Predictors for likelihood of corneal transplantation in keratoconus.The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation.Bayesian assessment of sample size for clinical trials of cost-effectiveness.Designing a non-inferiority study in kidney transplantation: a case study.Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.Robust meta-analytic-predictive priors in clinical trials with historical control information.Calculating partial expected value of perfect information via Monte Carlo sampling algorithms.Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?Dealing with skewed cost data.Practical Bayesian analysis of a simple logistic regression: predicting corneal transplants.Probabilistic sensitivity analysis of complex models: a Bayesian approachAssurance in clinical trial designGaussian process emulation of dynamic computer codesMonte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVAEliciting expert judgements about a set of proportionsAdvances in Modeling Model Discrepancy: Comment on Wu and Browne (2015)Probabilistic sensitivity analysis for NICE technology assessment: not an optional extraIncorporation of uncertainty in health economic modelling studiesFactors Influencing Post-operative Hospital Stay after Transurethral Resection of the Prostate Gland
P50
Q30654009-6B574CC2-CF9F-422F-8BA3-1E54349DB2A5Q30771605-5FEE1C14-D1E0-4CD2-9B81-E64A55471961Q30775597-9B4A3146-145D-4D3C-B6E2-8D35886575AEQ30927451-1949B5CD-FD24-4F05-BB58-8FCD2BBE15BFQ31032975-330B0857-B7C8-4F3A-A017-A610B1A2F481Q31070864-7BB3CB59-E7F9-4454-95B9-450C33ABC998Q31083950-C08C1867-D631-48CF-8D00-EA04E4C073B6Q33397837-26B3C2DB-856C-4005-9C89-171C525CE3C8Q33914367-6873A101-93D9-41FA-BE7F-F5B79A6534D9Q34367829-4A540689-33BF-4E94-8BC6-1EE4FB57B6EDQ34778011-E4214360-BD1D-4C3B-8B23-23EE6C230504Q35040675-2E4970FF-AD4B-46A7-99F9-6B4971949740Q36647448-B80F03FF-8CC5-42B5-90EB-F241B93A1E9FQ39894283-0B5D1599-FC9F-44DC-9429-87EC2E473D5EQ43453252-0B5D558E-339C-4FAE-9649-77C7579B68B3Q43913784-F23F78BF-AAA0-4970-8015-950B7476493CQ47209452-90B82391-00B1-44DB-B221-CB2B3411930DQ48110440-6A983BCF-14E2-4394-A03A-F715E09B7746Q51003614-5D24A472-43C0-4CBC-B1CC-7B7016813FDCQ51018509-2C0AF607-B2C8-40A6-9F7E-F22992DA1EAAQ51625586-2BDBB9D9-5DC3-4FF5-845C-8015051EA4B2Q52026392-495AD66B-39F0-4B52-81A0-215685CDB7B0Q52051080-725B46DD-1234-495C-9DC7-58D1DF620BA8Q52473642-49E4ED7C-1247-4EA3-BCFB-F34D865DFF2FQ56385622-C54E2672-96AD-422D-BAB3-3A5FCA999CCEQ57493663-DD0B5B12-301C-4160-9F88-3AF97C1C47C8Q58420694-9381BBE8-128B-4343-B21F-8BB6327BAFE2Q59297509-891B65E9-6C1E-4D6B-85E9-398C00D17244Q60215163-AC69761E-6448-4B8C-94D4-126E8F7DF7E3Q61856157-B22DDACF-2DB1-4DA0-90AC-6364E70A952BQ61856226-08FE9C5D-AF54-4399-AA33-CCEBF5D13B35Q61856229-28B28866-365F-438E-81B9-A0E8E18740EFQ61856272-D56D2290-B6C0-4732-A0C1-82286CC6D4F3
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Anthony O'Hagan
@ast
Anthony O'Hagan
@en
Anthony O'Hagan
@es
Anthony O'Hagan
@nl
Anthony O'Hagan
@sl
type
label
Anthony O'Hagan
@ast
Anthony O'Hagan
@en
Anthony O'Hagan
@es
Anthony O'Hagan
@nl
Anthony O'Hagan
@sl
altLabel
Tony O'Hagan
@en
prefLabel
Anthony O'Hagan
@ast
Anthony O'Hagan
@en
Anthony O'Hagan
@es
Anthony O'Hagan
@nl
Anthony O'Hagan
@sl
P1006
P214
P244
P1006
P1053
B-2992-2016
P106
P21
P214
P244
P2456
P31
P3829
P496
0000-0002-7994-0702
P569
1948-01-01T00:00:00Z
P734
P735
P7859
lccn-n87914552